106 related articles for article (PubMed ID: 38739808)
1. HER2 siRNA Facilitated Gene Silencing Coupled with Doxorubicin Delivery: A Dual Responsive Nanoplatform Abrogates Breast Cancer.
M G A; K S A; B S U; P L R; H P S; J S; Joseph MM; T T S
ACS Appl Mater Interfaces; 2024 May; 16(20):25710-25726. PubMed ID: 38739808
[TBL] [Abstract][Full Text] [Related]
2. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment.
Zheng D; Wan C; Yang H; Xu L; Dong Q; Du C; Du J; Li F
Int J Nanomedicine; 2020; 15():10007-10028. PubMed ID: 33376321
[TBL] [Abstract][Full Text] [Related]
3. A dual-targeted hyaluronic acid-gold nanorod platform with triple-stimuli responsiveness for photodynamic/photothermal therapy of breast cancer.
Xu W; Qian J; Hou G; Wang Y; Wang J; Sun T; Ji L; Suo A; Yao Y
Acta Biomater; 2019 Jan; 83():400-413. PubMed ID: 30465921
[TBL] [Abstract][Full Text] [Related]
4. Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer.
Dong Q; Wan C; Yang H; Zheng D; Xu L; Zhou Z; Xie S; Du J; Li F
J Biomater Appl; 2020 Sep; 35(3):430-445. PubMed ID: 32515640
[TBL] [Abstract][Full Text] [Related]
5. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
6. Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer.
Zhang C; Zhang F; Han M; Wang X; Du J; Zhang H; Li W
Sci Rep; 2020 Dec; 10(1):22015. PubMed ID: 33328545
[TBL] [Abstract][Full Text] [Related]
7. A DM1-doped porous gold nanoshell system for NIR accelerated redox-responsive release and triple modal imaging guided photothermal synergistic chemotherapy.
Xu P; Wang R; Yang W; Liu Y; He D; Ye Z; Chen D; Ding Y; Tu J; Shen Y
J Nanobiotechnology; 2021 Mar; 19(1):77. PubMed ID: 33741008
[TBL] [Abstract][Full Text] [Related]
8. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.
Salehi Khesht AM; Karpisheh V; Sahami Gilan P; Melnikova LA; Olegovna Zekiy A; Mohammadi M; Hojjat-Farsangi M; Majidi Zolbanin N; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
Int J Biol Macromol; 2021 Sep; 186():849-863. PubMed ID: 34245737
[TBL] [Abstract][Full Text] [Related]
9. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
10. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
11. Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells.
Yi Y; Kim HJ; Zheng M; Mi P; Naito M; Kim BS; Min HS; Hayashi K; Perche F; Toh K; Liu X; Mochida Y; Kinoh H; Cabral H; Miyata K; Kataoka K
J Control Release; 2019 Feb; 295():268-277. PubMed ID: 30639386
[TBL] [Abstract][Full Text] [Related]
12. CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice.
Mondal L; Mukherjee B; Das K; Bhattacharya S; Dutta D; Chakraborty S; Pal MM; Gaonkar RH; Debnath MC
Int J Nanomedicine; 2019; 14():8073-8094. PubMed ID: 31632019
[TBL] [Abstract][Full Text] [Related]
13. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX
Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells.
Cristofolini T; Dalmina M; Sierra JA; Silva AH; Pasa AA; Pittella F; Creczynski-Pasa TB
Mater Sci Eng C Mater Biol Appl; 2020 Apr; 109():110555. PubMed ID: 32228895
[TBL] [Abstract][Full Text] [Related]
15. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.
Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
[TBL] [Abstract][Full Text] [Related]
16. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference.
Tan WB; Jiang S; Zhang Y
Biomaterials; 2007 Mar; 28(8):1565-71. PubMed ID: 17161865
[TBL] [Abstract][Full Text] [Related]
17. Gold Nanoparticles Mediated Drug-Gene Combinational Therapy for Breast Cancer Treatment.
Shrestha B; Wang L; Zhang H; Hung CY; Tang L
Int J Nanomedicine; 2020; 15():8109-8119. PubMed ID: 33116521
[TBL] [Abstract][Full Text] [Related]
18. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting HER3 Hyperphosphorylation in HER2-Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells.
Villar-Alvarez E; Golán-Cancela I; Pardo A; Velasco B; Fernández-Vega J; Cambón A; Al-Modlej A; Topete A; Barbosa S; Costoya JA; Taboada P
Small; 2023 Dec; 19(50):e2303934. PubMed ID: 37632323
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
